CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia-A case report

Ruth M Urbantat; Valentin Popper; Elisabeth Menschel; Michael Pfeilstöcker; Ernst Forjan; Alexander Nader; Catherine R Sieghart; Felix Keil; Elisabeth Koller

doi:10.1002/ccr3.3909

CPX-351 (Vyxeos^®) can cause severe rash in acute myeloid leukemia-A case report

Clin Case Rep. 2021 Feb 12;9(4):1933-1936. doi: 10.1002/ccr3.3909. eCollection 2021 Apr.

Authors

Affiliations

¹ OeGK-Hanusch Krankenhaus Vienna Austria.
² Medizinische Universität Vienna Austria.
³ Charité - Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt-Universität zu Berlin Berlin Germany.
⁴ Berlin Institute of Health Berlin Germany.

Abstract

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Keywords: CPX‐351; acute myeloid leukemia; elderly; rash.

Publication types

Case Reports